INmune Bio, Inc. Prices Public Offering of Common Stock

LA JOLLA, Calif, July 16, 2020 (GLOBE NEWSWIRE) —  INmune Bio, Inc. (NASDAQ: INMB) (the “Company” or “INmune”), a clinical-stage immunology company focused on developing treatments that harness a patient’s innate immune system to fight disease, today announced today the pricing of its  underwritten public offering of an aggregate of 2,173,914 shares of its common stock at a public

Click to view original post

Advertise With Us